Myelofibrosis (MF) Leukemic Transformation (LT) in the Era of Ruxolitinib and Genomics: Characteristics and Outcomes

被引：0
|
作者：
Falchi, Lorenzo
Chihara, Dai
Bose, Prithviraj
Estrov, Zeev
Kantarjian, Hagop M.
Ravandi, Farhad
Verstovsek, Srdan
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4185
引用
收藏
页数：2
相关论文
共 26 条
  • [21] Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen-Single-Center Analysis
    Machherndl-Spandl, Sigrid
    Hannouf, Sarah
    Nikoloudis, Alexander
    Zach, Otto
    Strassl, Irene
    Kaynak, Emine
    Webersinke, Gerald
    Gruber-Rossipal, Christine
    Rumpold, Holger
    Schimetta, Wolfgang
    Clausen, Johannes
    Buxhofer-Ausch, Veronika
    CANCERS, 2024, 16 (19)
  • [22] LONG-TERM OUTCOMES OF RUXOLITINIB (RUX) THERAPY IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF): 5-YEAR FINAL EFFICACY AND SAFETY ANALYSIS FROM COMFORT-I
    Verstovsek, S.
    Mesa, R. A.
    Gotlib, J. R.
    Gupta, V.
    DiPersio, J. F.
    Catalano, J. V.
    Deininger, M. W.
    Miller, C. B.
    Silver, R. T.
    Talpaz, M.
    Winton, E. F.
    Harvey, J. H., Jr.
    Arcasoy, M. O.
    Hexner, E. O.
    Lyons, R. M.
    Paquette, R.
    Raza, A.
    Jones, M.
    Kornacki, D.
    Sun, K.
    Kantarjian, H.
    HAEMATOLOGICA, 2016, 101 : 162 - 163
  • [23] LONG-TERM OUTCOMES FROM A PHASE 3 STUDY COMPARING RUXOLITINIB WITH BEST AVAILABLE THERAPY ( BAT) FOR THE TREATMENT OF MYELOFIBROSIS (MF): A 3-YEAR UPDATE OF COMFORT-II
    Vannucchi, A.
    Cervantes, F.
    Niederwieser, D.
    Sirulnik, A.
    Stalbovskaya, V.
    McQuitty, M.
    Levy, R.
    Passamonti, F.
    Barbui, T.
    Gisslinger, H.
    Knoops, L.
    Harrison, C.
    Barosi, G.
    Kiladjian, J.
    HAEMATOLOGICA, 2013, 98 : 456 - 457
  • [24] The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 x 109/L to < 100 x 109/L) at Baseline
    Guglielmelli, Paola
    Kiladjian, Jean-Jacques
    Vannucchi, Alessandro M.
    Duan, Ming-hui
    Meng, Haitao
    Pan, Ling
    He, Guangsheng
    Verstovsek, Srdan
    Boyer-Perrard, Francoise
    Barraco, Fiorenza
    Niederwieser, Dietger
    Liberati, Anna Marina
    Harrison, Claire
    Roussou, Pantelia
    Wroclawska, Monika
    Majidi, Kevin
    te Boekhorst, Peter A. W.
    Gisslinger, Heinz
    BLOOD, 2020, 136
  • [25] Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes
    Ghorab, Ahmad
    Jain, Preetesh
    Kantarjian, Hagop M.
    Kanagal-Shamanna, Rashmi
    Jabbour, Elias J.
    Sasaki, Koji
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Bose, Prithviraj
    Yilmaz, Musa
    Naqvi, Kiran
    Wierda, William G.
    Verstovsek, Srdan
    Jain, Nitin
    Estrov, Zeev
    Ravandi, Farhad
    O'Brien, Susan M.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [26] Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes.
    Ghorab, Ahmad
    Kantarjian, Hagop M.
    Jain, Preetesh
    Kanagal-Shamanna, Rashmi
    Jabbour, Elias
    Sasaki, Koji
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    Bose, Prithviraj
    Yilmaz, Musa
    Naqvi, Kiran
    Wierda, William G.
    Verstovsek, Srdan
    Jain, Nitin
    Estrov, Zeev
    Ravandi, Farhad
    O'Brien, Susan Mary
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
123